Reports
Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
The global diabetic neuropathy market attained a value of USD 4.37 billion in 2020. The market is further expected to grow in the forecast period of 2022-2027 at a CAGR of 8.12% to reach USD 6.98 billion by 2026.
Geographically, North America accounts for a significant market share in the diabetic neuropathy industry. The rising prevalence of diabetes and the growing complications among patients, owing to the increased consumption of processed food and sugary beverages in the region, are driving the demand for diabetic neuropathy treatment.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The availability of advanced healthcare facilities and treatment options and the increasing innovations in drugs are the major factors contributing to the growth of the market in the region. In addition, the increasing health awareness among the population and the favourable reimbursement policies in the region are further propelling the diabetic neuropathy industry growth in North America.
Diabetic neuropathy is nerve damage caused due to diabetes. Diabetic neuropathy damages the nerves throughout the body parts. Symptoms of diabetic neuropathy are numbness, pain, problems in the digestive system, blood vessels, urinary tract, and heart.
By type, the market can be divided into:
The market can be broadly categorised on the basis of treatment methods into:
Among these, the antidepressants segment can be further divided based on type into Duloxetine (Cymbalta), Nortriptyline (Pamelor, Aventyl), and Desipramine (Norpramin).
The EMR report looks into the regional markets of diabetic neuropathy like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The increasing geriatric population, coupled with the increasing consumption of sugar, is leading to a rise in cases of diabetes. An increase in the number of diabetic patients globally is leading to a rise in demand for diabetic neuropathy treatment. In addition, the increasing government expenditure to improve healthcare facilities is further contributing to the market growth. In the forecast period, the rapid advancements in technology and the increasing investments by the key market players are expected to drive the growth of the diabetic neuropathy industry. The increase in research and development activities to launch new drugs that can help cure diabetes is anticipated to create significant opportunities for the market expansion in the coming years.
The report presents a detailed analysis of the following key players in the global diabetic neuropathy market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2021 |
Historical Period | 2017-2021 |
Forecast Period | 2022-2027 |
Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Treatment Methods, Region |
Breakup by Type | Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy |
Breakup by Treatment Methods | Antidepressants, Anti-seizure Medications, Anticonvulsants, Electrical Nerve Stimulation, Topical Medications, Others |
Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
Companies Covered | NeuroMetrix, Inc, Allergan PLC, Pfizer, Inc, Eli Lilly and Company, Novartis AG, Others |
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Diabetic Neuropathy Market Analysis
8.1 Key Industry Highlights
8.2 Global Diabetic Neuropathy Historical Market (2017-2021)
8.3 Global Diabetic Neuropathy Market Forecast (2022-2027)
8.4 Global Diabetic Neuropathy Market by Type
8.4.1 Peripheral Neuropathy
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Autonomic Neuropathy
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Proximal Neuropathy
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Focal Neuropathy
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2017-2021)
8.4.4.3 Forecast Trend (2022-2027)
8.5 Global Diabetic Neuropathy Market by Treatment Methods
8.5.1 Antidepressants
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.1.4 Breakup by Type
8.5.1.4.1 Duloxetine (Cymbalta)
8.5.1.4.2 Nortriptyline (Pamelor, Aventyl)
8.5.1.4.3 Desipramine (Norpramin)
8.5.2 Anti-seizure Medications
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Anticonvulsants
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.5.4 Electrical Nerve Stimulation
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2017-2021)
8.5.4.3 Forecast Trend (2022-2027)
8.5.5 Topical Medications
8.5.5.1 Market Share
8.5.5.2 Historical Trend (2017-2021)
8.5.5.3 Forecast Trend (2022-2027)
8.5.6 Others
8.6 Global Diabetic Neuropathy Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 NeuroMetrix, Inc
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Allergan PLC
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Pfizer, Inc
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Eli Lilly and Company
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Novartis AG
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Diabetic Neuropathy Market: Key Industry Highlights, 2016 and 2026
2. Global Diabetic Neuropathy Historical Market: Breakup by Type (USD Billion), 2017-2021
3. Global Diabetic Neuropathy Market Forecast: Breakup by Type (USD Billion), 2022-2027
4. Global Diabetic Neuropathy Historical Market: Breakup by Treatment Methods (USD Billion), 2017-2021
5. Global Diabetic Neuropathy Market Forecast: Breakup by Treatment Methods (USD Billion), 2022-2027
6. Global Diabetic Neuropathy Historical Market: Breakup by Region (USD Billion), 2017-2021
7. Global Diabetic Neuropathy Market Forecast: Breakup by Region (USD Billion), 2022-2027
8. North America Diabetic Neuropathy Historical Market: Breakup by Country (USD Billion), 2017-2021
9. North America Diabetic Neuropathy Market Forecast: Breakup by Country (USD Billion), 2022-2027
10. Europe Diabetic Neuropathy Historical Market: Breakup by Country (USD Billion), 2017-2021
11. Europe Diabetic Neuropathy Market Forecast: Breakup by Country (USD Billion), 2022-2027
12. Asia Pacific Diabetic Neuropathy Historical Market: Breakup by Country (USD Billion), 2017-2021
13. Asia Pacific Diabetic Neuropathy Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Latin America Diabetic Neuropathy Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Latin America Diabetic Neuropathy Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Middle East and Africa Diabetic Neuropathy Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Middle East and Africa Diabetic Neuropathy Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Global Diabetic Neuropathy Market Structure
In 2020, the global diabetic neuropathy market attained a value of nearly USD 4.37 billion.
The market is projected to grow at a CAGR of 8.12% between 2022 and 2027.
The major drivers of the industry, such as the rising disposable incomes, increasing health awareness, advancement in technology, increasing demand for natural dietary supplements, increasing geriatric population, increase in research and development activities, and growing innovations are driving the market growth.
The key market trends guiding the growth of the industry include the the increasing consumption of sugar and rise in cases of diabetes.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The types of diabetic neuropathy in the industry are peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy.
The major treatment methods in the market are antidepressants, anti-seizure medications, anticonvulsants, electrical nerve stimulation, and topical medications, among others. Among these, the antidepressants segment can be further divided based on type into duloxetine (cymbalta), nortriptyline (pamelor, aventyl), and desipramine (norpramin).
The major players in the industry are NeuroMetrix, Inc, Allergan PLC, Pfizer, Inc, Eli Lilly and Company, and Novartis AG, among others.
The global diabetic neuropathy market attained a value of USD 4.37 billion in 2020, driven by the growing geriatric population. Aided by the growing technological advancements and rise in cases of diabetes, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 8.12%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its types, the diabetic neuropathy industry can be segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. On the basis of treatment methods, the market is segmented into antidepressants, anti-seizure medications, anticonvulsants, electrical nerve stimulation, and topical medications, among others. Among these, the antidepressants segment can be further divided based on type into duloxetine (cymbalta), nortriptyline (pamelor, aventyl), and desipramine (norpramin). The major regional markets for diabetic neuropathy are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include NeuroMetrix, Inc, Allergan PLC, Pfizer, Inc, Eli Lilly and Company, and Novartis AG, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.